Approved Uses

As an adjunct to diet, CRESTOR^® (rosuvastatin calcium) is indicated to lower LDL-C, raise HDL-C, and is approved to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower cholesterol to target levels.¹

CRESTOR is indicated to reduce the risk of myocardial infarction, stroke and arterial revascularization procedures in patients without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men ≥50 and women ≥60), high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease.¹

Reduce LDL-C and raise HDL-C

CRESTOR is indicated along with diet to reduce elevated total-C, LDL-C, ApoB, non-HDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.¹

Slow the progression of atherosclerosis

As an adjunct to diet, CRESTOR is approved to slow the progression of atherosclerosis in at-risk patients as part of a treatment strategy to lower total-C and LDL-C to target levels.¹

Atherosclerosis is a common, progressive vascular disease.²

Atherosclerotic plaques can progress significantly before they are detected.^3,4

Is your statin of choice indicated to slow the progression of atherosclerosis?

Lescol and Lescol XL are registered trademarks of Novartis Pharmaceuticals Corporation.
Mevacor is a registered trademark of Merck & Co., Inc.
Pravachol is a registered trademark of Bristol-Myers Squibb Company.
Lipitor is a registered trademark of Pfizer Inc.
Livalo is a trademark of the Kowa group of companies.
Zocor is a registered trademark of Merck & Co., Inc.
Vytorin is a registered trademark of MSP Singapore Company, LLC.

Help your at-risk patients understand atherosclerosis

There is an opportunity to raise awareness about atherosclerosis. The ongoing dialogue you have with your at-risk patients builds greater understanding about this prevalent health condition. By educating your patients about atherosclerosis, we can

Raise awareness about the disease
Communicate the importance of cholesterol management
Call attention to the link between cholesterol and arterial plaque buildup
Motivate at-risk patients to take better care of their arteries

See how AstraZeneca is helping educate at-risk patients about atherosclerosis.

Primary prevention of CVD indication

Important Safety Information for CRESTOR Tablets

CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers
Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, lopinavir/ritonavir, or atazanavir/ritonavir
Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended
CRESTOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease
CRESTOR significantly increased INR in patients receiving coumarin anticoagulants. In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs
Dipstick-positive proteinuria and microscopic hematuria were observed among patients treated with CRESTOR. These findings were more frequent in patients taking CRESTOR 40 mg, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, dose reduction should be considered for patients on CRESTOR therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing
Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including CRESTOR
In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)^#‡‡
The dose range for CRESTOR is 5 mg to 40 mg orally once daily. The usual starting dose is 10 mg to 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose. After initiation or upon titration of CRESTOR, lipid levels should be analyzed within 2 to 4 weeks and the dosage adjusted accordingly. CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg

Important Safety Information from the JUPITER Study

A higher percentage of rosuvastatin-treated patients vs placebo-treated patients (6.6% and 6.2%, respectively) discontinued study medication due to an adverse event, irrespective of treatment causality. Myalgia was the most common adverse reaction that led to treatment discontinuation
In JUPITER, there was a significantly higher frequency of diabetes mellitus reported in patients taking rosuvastatin (2.8%) vs patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in rosuvastatin-treated patients compared to placebo-treated patients. The number of patients with HbA1c >6.5% at the end of the trial was significantly higher in rosuvastatin-treated patients vs placebo-treated patients
The most common adverse reactions reported were myalgia (7.6% vs 6.6%), arthralgia (3.8% vs 3.2%), constipation (3.3% vs 3.0%), and nausea (2.4% vs 2.3%) for CRESTOR vs placebo, respectively

Indications

CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels
CRESTOR is indicated to reduce the risk of myocardial infarction, stroke, and arterial revascularization procedures in patients without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men ≥50 and women ≥60), high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease

Read full Prescribing Information (PDF - 152k)

Please see the full Prescribing Information available at CrestorTouchPoints.com

CRESTOR is licensed from SHIONOGI & CO, LTD, Osaka, Japan.

CRESTOR is a registered trademark of the AstraZeneca group of companies.

This product information is intended for US health care professionals only.

Approved Uses

Reduce LDL-C and raise HDL-C

CRESTOR is indicated along with diet to reduce elevated total-C, LDL-C, ApoB, non-HDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.¹

Slow the progression of atherosclerosis

As an adjunct to diet, CRESTOR is approved to slow the progression of atherosclerosis in at-risk patients as part of a treatment strategy to lower total-C and LDL-C to target levels.¹

Atherosclerosis is a common, progressive vascular disease.²

Atherosclerotic plaques can progress significantly before they are detected.^3,4

Is your statin of choice indicated to slow the progression of atherosclerosis?

Help your at-risk patients understand atherosclerosis

Raise awareness about the disease
Communicate the importance of cholesterol management
Call attention to the link between cholesterol and arterial plaque buildup
Motivate at-risk patients to take better care of their arteries

See how AstraZeneca is helping educate at-risk patients about atherosclerosis.

Primary prevention of CVD indication

Important Safety Information for CRESTOR Tablets

CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers
Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, lopinavir/ritonavir, or atazanavir/ritonavir
Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended
CRESTOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease
CRESTOR significantly increased INR in patients receiving coumarin anticoagulants. In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs
Dipstick-positive proteinuria and microscopic hematuria were observed among patients treated with CRESTOR. These findings were more frequent in patients taking CRESTOR 40 mg, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, dose reduction should be considered for patients on CRESTOR therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing
Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including CRESTOR
In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)^#‡‡
The dose range for CRESTOR is 5 mg to 40 mg orally once daily. The usual starting dose is 10 mg to 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose. After initiation or upon titration of CRESTOR, lipid levels should be analyzed within 2 to 4 weeks and the dosage adjusted accordingly. CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg

Important Safety Information from the JUPITER Study

A higher percentage of rosuvastatin-treated patients vs placebo-treated patients (6.6% and 6.2%, respectively) discontinued study medication due to an adverse event, irrespective of treatment causality. Myalgia was the most common adverse reaction that led to treatment discontinuation
In JUPITER, there was a significantly higher frequency of diabetes mellitus reported in patients taking rosuvastatin (2.8%) vs patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in rosuvastatin-treated patients compared to placebo-treated patients. The number of patients with HbA1c >6.5% at the end of the trial was significantly higher in rosuvastatin-treated patients vs placebo-treated patients
The most common adverse reactions reported were myalgia (7.6% vs 6.6%), arthralgia (3.8% vs 3.2%), constipation (3.3% vs 3.0%), and nausea (2.4% vs 2.3%) for CRESTOR vs placebo, respectively

Indications

CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels
CRESTOR is indicated to reduce the risk of myocardial infarction, stroke, and arterial revascularization procedures in patients without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men ≥50 and women ≥60), high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease

Read full Prescribing Information (PDF - 152k)

Please see the full Prescribing Information available at CrestorTouchPoints.com
CRESTOR is licensed from SHIONOGI & CO, LTD, Osaka, Japan.

CRESTOR is a registered trademark of the AstraZeneca group of companies.

This product information is intended for US health care professionals only.

Role:		Specialty:

Individual NPI Number: Your NPI number is used to confirm you are a licensed health care provider. Don't know your NPI? Find it now

First Name:		Last Name:

Individual NPI Number: Your NPI number is used to confirm you are a licensed health care provider. Don't know your NPI? Find it now

E-mail Address:

Password:		Confirm Password:

E-mail Address:

Password:		Confirm Password:

Approved Uses

Reduce LDL-C and raise HDL-C

Slow the progression of atherosclerosis

Is your statin of choice indicated to slow the progression of atherosclerosis?

Help your at-risk patients understand atherosclerosis

Primary prevention of CVD indication

Important Safety Information for CRESTOR Tablets

Important Safety Information from the JUPITER Study

Indications

Lowering LDL-C

Get updates about CRESTOR

Approved Uses

Reduce LDL-C and raise HDL-C

Slow the progression of atherosclerosis

Is your statin of choice indicated to slow the progression of atherosclerosis?

Help your at-risk patients understand atherosclerosis

Primary prevention of CVD indication

Important Safety Information for CRESTOR Tablets

Important Safety Information from the JUPITER Study

Indications

Personal Account Specialist

Register for AZ TouchPoints

Enter Your InformationAll fields required

Create Your Account

Register for AZ TouchPoints

Enter Your InformationAll fields required

Create Your Account

Log In

Not Registered?

Forgot Your Password?

Password Sent

Log In

Please Log In to Access This Content

Not Registered?

Log In

Forgot Your Password?

AZ TouchPoints Web Sites

CRESTOR®

How Can We Help You?

Visit the Suite of AZ TouchPoints Web Sites

CRESTOR®

AZ Medical Information Support

CRESTOR^®

CRESTOR^®